Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P26718
UPID:
NKG2D_HUMAN
Alternative names:
Killer cell lectin-like receptor subfamily K member 1; NK cell receptor D; NKG2-D-activating NK receptor
Alternative UPACC:
P26718; A8K7K5; A8K7P4; Q9NR41
Background:
NKG2-D type II integral membrane protein, also known as Killer cell lectin-like receptor subfamily K member 1, plays a pivotal role in the immune system. It activates and costimulates killer (NK) cells and CD8(+) T-cells upon binding to stress-induced ligands on tumor and virus-infected cells, leading to cytotoxic activity.
Therapeutic significance:
Understanding the role of NKG2-D type II integral membrane protein could open doors to potential therapeutic strategies.